In several phase I and phase II trials, concomitant treatment with imatinib and vaccines against BCR–ABL1 epitopes showed an enhanced anti-tumor activity in patients with CML [92, 93]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.